Belvedere Trading
BCAB icon

Belvedere Trading’s BioAtla BCAB Stock Holding History

Belvedere Trading’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-235
Closed -$40.4K – 700
2024
Q1 		$40.4K Buy
+235
New +$29.2K ﹤0.01% 522
2023
Q4 		– Sell
-193
Closed -$16.4K – 810
2023
Q3 		$16.4K Buy
+193
New +$24.6K ﹤0.01% 520

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
SAM
Scion Asset Management Saratoga, California $1.38B AUM 43.96% 1-Year Est. Return

Belvedere Trading's BCAB Position: Q2 2024 in Review

Belvedere Trading sold out of BioAtla (BCAB) in Q2 2024, closing a stake of 235 shares — an estimated $40.4K sold.

Belvedere Trading first reported a position in BCAB in Q3 2023 and held it in 2 quarters. The position peaked at $40.4K in Q1 2024. 80 funds tracked by Wall St. Rank hold BCAB as of Q2 2024.

  • Belvedere Trading reported no remaining BioAtla position as of Q2 2024 after selling out during the quarter.
  • Belvedere Trading sold 235 BioAtla shares in Q2 2024, an estimated $40.4K.
  • Belvedere Trading first reported a position in BioAtla in Q3 2023 and held it in 2 quarters.
  • Belvedere Trading's BioAtla position peaked at $40.4K in Q1 2024.
  • 80 funds tracked by Wall St. Rank held BioAtla as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.